Dashboard
Manage Tickers

MRKMerck & Co., Inc.

NYSE merck.com


$ 130.92 $ -0.85 (-0.65 %)    

Thursday, 16-May-2024 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 451.64 $ -0.92 (-0.2 %)
DIA $ 399.14 $ -0.07 (-0.02 %)
SPY $ 528.49 $ -1.09 (-0.21 %)
TLT $ 92.06 $ -0.09 (-0.1 %)
GLD $ 220.06 $ -0.86 (-0.39 %)
$ 130.88
$ 131.60
$ 0.00 x 0
$ 0.00 x 0
$ 130.79 - $ 131.72
$ 97.81 - $ 133.10
5,481,674
na
331.49B
$ 0.33
$ 143.75
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-03-2024 03-31-2024 10-Q
2 02-26-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-05-2023 03-31-2023 10-Q
6 02-24-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-25-2022 12-31-2021 10-K
11 11-05-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-26-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 02-27-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 02-27-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-08-2017 06-30-2017 10-Q
29 05-09-2017 03-31-2017 10-Q
30 02-28-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-08-2016 06-30-2016 10-Q
33 05-09-2016 03-31-2016 10-Q
34 02-26-2016 12-31-2015 10-K
35 11-05-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 02-27-2015 12-31-2014 10-K
39 11-10-2014 09-30-2014 10-Q
40 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

check-out-what-whales-are-doing-with-mrk
Check Out What Whales Are Doing With MRK
05/16/2024 18:36:35

pfizer-astrazeneca-sanofi-and-mainz-biomed-to-uplevel-europes-pharma-game
Pfizer, AstraZeneca, Sanofi And Mainz Biom...
05/16/2024 12:51:36

On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will...

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
05/15/2024 17:35:22

merck-plans-to-present-new-data-at-2024-asco-annual-meeting-showing-advancements-in-novel-oncology-treatment-approaches-across-broad-portfolio-and-diverse-pipeline
Merck Plans To Present New Data At 2024 AS...
05/15/2024 10:53:49

merck-halts-skin-cancer-drug-trial-on-high-discontinuation-rate---a-setback-in-high-risk-melanoma-treatment
Merck Halts Skin Cancer Drug Trial On High...
05/13/2024 15:09:28

Merck halts vibostolimab and pembrolizumab coformulation arm in KeyVibe-010 Phase 3 trial for high-risk melanoma due to higher ...

merck-discontinued-vibostolimab-and-pembrolizumab-coformulation-arm-of-phase-3-keyvibe-010-trial-compared-to-keytruda-alone-as-adjuvant-treatment-for-patients-with-resected-high-risk-melanoma
Merck Discontinued Vibostolimab And Pembro...
05/13/2024 10:48:06

At a pre-planned analysis, data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futili...

whats-going-on-with-medical-therapeutic-firm-aethlon-medical-on-friday
What's Going On With Medical Therapeutic F...
05/10/2024 14:46:21

Aethlon Medical unveils results in removing extracellular vesicles (EVs) from plasma. Preclinical evidence supports upcoming ph...

mercks-phase-3-keynote-b21-trial-of-keytruda-in-combination-with-chemotherapy-as-adjuvant-treatment-with-or-without-radiotherapy-did-not-meet-its-primary-endpoint-of-disease-free-survival-for-newly-diagnosed-high-risk-endometrial-cancer-after-surgery
Merck's Phase 3 KEYNOTE-B21 Trial Of Keytr...
05/09/2024 11:30:54

merck-announces-health-canada-approval-of-keytruda-for-adult-patients-with-locally-advanced-unresectable-or-metastatic-biliary-tract-carcinoma-in-combination-with-gemcitabine-based-chemotherapy
Merck Announces Health Canada Approval Of ...
05/09/2024 11:11:46

jim-cramer-advises-investors-to-brace-for-economic-slowdown-shares-tips-to-maintain-balanced-portfolio-im-not-telling-you-to-relax
Jim Cramer Advises Investors To Brace For ...
05/08/2024 06:26:57

Jim Cramer, the host of CNBC's "Mad Money," has warned investors about the current state of the economy and suggest...

Core News & Articles
CytomX Therapeutics Announces Clinical Col...
05/07/2024 21:26:01

- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
05/07/2024 17:35:23

market-analysis-merck-amp-co-and-competitors-in-pharmaceuticals-industry
Market Analysis: Merck & Co And Compet...
05/07/2024 15:00:45

merck--co-anticipates-actions-under-2024-restructuring-program-will-result-in-cumulative-annual-net-cost-savings-of-about-750m-by-end-of-2031-expects-to-record-charges-of-about-800m-in-2024-related-to-2024-restructuring-program
Merck & Co Anticipates Actions Under 2024 ...
05/03/2024 20:20:26

-SEC Filing

serum-institute-of-india-inks-large-scale-supply-deal-for-bcg-use-in-immunitybios-bladder-cancer-combo-therapy
Serum Institute of India Inks Large-Scale ...
05/03/2024 16:19:55

Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to expa...

job-market-cools-in-april-payrolls-miss-forecasts-wages-rise-less-than-expected-updated
Job Market Cools In April: Payrolls Miss F...
05/03/2024 12:58:14

U.S. labor market misses April expectations, signaling slower economic growth and potential interest rate cuts. Stocks rise, Tr...

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
05/02/2024 17:35:24

merck-reports-progress-on-the-cancer-front-as-it-prepares-for-keytruda-patent-expiration
Merck Reports Progress On The Cancer Front...
05/02/2024 16:53:54

After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just repo...

mercks-phase-3-keynote-811-trial-of-keytruda-met-dual-primary-endpoint-of-overall-survival-as-first-line-treatment-of-her2-positive-advanced-gastric-or-gastroesophageal-junction-adenocarcinoma
Merck's Phase 3 KEYNOTE-811 Trial Of Keytr...
05/01/2024 11:17:18

merck-announces-data-for-v116-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-for-adults
Merck Announces Data For V116, Investigati...
04/29/2024 13:02:29

Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infecti...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION